Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• Botulinum neurotoxins are highly potent poisons produced by the Clostridium genus of anaerobic bacteria.
• the active neurotoxin is a heterodimer between a 100 kDa heavy chain (HC) and 50 kDa light chain (LC).
• HC 100 kDa heavy chain
• LC 50 kDa light chain
• the HC mediates selective binding to endosomal receptors on the presynaptic membrane of peripheral neurons.
• the LC translocates into the nerve terminal, where it specifically cleaves neuronal soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins essential for neurotransmitter release. Cleavage of SNARE proteins blocks assembly of core vesicle fusion complexes, preventing vesicle fusion and acetylcholine release. As the concentration of cleaved SNARE proteins increases, motor nerve terminals are unable to reliably elicit muscle contraction, causing muscle weakness that progresses to flaccid paralysis.
• SNARE neuronal soluble N-ethylmaleimide-sensitive factor attachment protein receptor
• BoNTs are considered Tier 1 select agents by the U.S. government.
• BoNT serotype A (BoNT/A) is the etiological agent responsible for approximately half of natural botulism cases in the United States and is also the active component in most neurotoxin-based pharmaceuticals. Neurotoxin-based pharmaceuticals, which are injected into muscle for medicinal or cosmetic purposes, can cause off-target effects when overdosed or misplaced. Off-target effects of localized BoNT injections can include unwanted localized muscle weakness or paralysis near the treatment site. Consequently, treatments for natural and iatrogenic BoNT/A botulism are a high priority.
• SMIs small molecule inhibitors
• development of SMIs is complicated by multiple factors, including an expansive substrate-enzyme interface, topologically constrained active site, large degree of conformational flexibility and need for multiple SMIs to block the structurally diverse toxin serotypes. Consequently, no SMIs have been approved to date.
• intraneuronal delivery of therapeutic antibodies was recently reported to have antidotal efficacy in non-human primates, with physiological reversal of botulism symptoms occurring over days.
• the present disclosure relates to methods of treating botulism, wherein the method comprises administering an effective amount of 3,4-diaminopyridine, or a pharmaceutically acceptable salt thereof, via continuous infusion, via injection of a plurality of doses, or via oral administration of a plurality of doses.
• the present disclosure provides a method of treating botulism in a subject in need thereof comprising intravenously administering to the subject an effective amount of 3,4-diaminopyridine, or an equivalent amount of a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable vehicle via continuous infusion.
• the effective amount of 3,4-diaminopyridine is infused at a rate of about 0.5 mg/kg of the subject’s body weight per hour to about 3 mg/kg of the subject’s body weight per hour. [0008] In some aspects, the effective amount of 3,4-diaminopyridine is infused at a rate of about 1.4 mg/kg of the subject’s body weight per hour. [0009] In some aspects, the effective amount of 3,4-diaminopyridine is provided in a total daily dose ranging from about 80 mg to about 160 mg of 3,4-diaminopyridine, or the equivalent amount of the pharmaceutically acceptable salt thereof. [0010] In some aspects, the subject is a human subject.
• administering the 3,4-diaminopyridine or the equivalent amount of the pharmaceutically acceptable salt thereof, via continuous infusion achieves a steady-state plasma concentration of about 120 ng/mL of 3,4-diaminopyridine in the subject.
• the method comprises administering the total daily dose of 3,4- diaminopyridine or the equivalent amount of the pharmaceutically acceptable salt thereof, via continuous infusion for a plurality of consecutive days.
• the botulism is caused by botulinum neurotoxin serotype A.
• the botulism comprises localized botulinum neurotoxin intoxication.
• the present disclosure provides a method of treating botulism in a subject in need thereof comprising administering to the subject an effective amount of 3,4-diaminopyridine or an equivalent amount of a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable vehicle via a plurality of single bolus injections.
• each of the plurality of single bolus injections comprises about 1 mg to about 3 mg of 3,4-diaminopyridine, or the equivalent amount of the pharmaceutically acceptable salt thereof, per kg of the subject’s body weight.
• each of the plurality of single bolus injections comprises about 2 mg of 3,4-diaminopyridine, or the equivalent amount of the pharmaceutically acceptable salt thereof, per kg of the subject’s body weight.
• the effective amount of 3,4-diaminopyridine, or the equivalent amount of the pharmaceutically acceptable salt thereof is provided in a total daily dose ranging from about 80 mg to about 160 mg of 3,4-diaminopyridine.
• the subject is a human subject.
• administering the 3,4-diaminopyridine or the equivalent amount of the pharmaceutically acceptable salt thereof, via the plurality of single bolus injections achieves a steady-state plasma concentration of about 120 ng/mL of 3,4-diaminopyridine in the subject.
• the method comprises administering the total daily dose of 3,4- diaminopyridine or the equivalent amount of the pharmaceutically acceptable salt thereof, during each of a plurality of consecutive days.
• the botulism is caused by botulinum neurotoxin serotype A.
• the botulism comprises localized botulinum neurotoxin intoxication.
• the present disclosure provides a method of treating botulism in a subject in need thereof comprising orally administering to the subject an effective amount of 3,4-diaminopyridine phosphate salt.
• the effective amount of 3,4-diaminopyridine phosphate salt is provided in a total daily dose equivalent to about 80 mg to about 160 mg of 3,4- diaminopyridine freebase.
• the total daily dose of 3,4-diaminopyridine phosphate salt is administered in a plurality of single doses per day.
• orally administering the 3,4-diaminopyridine phosphate salt achieves a steady-state plasma concentration of about 120 ng/mL of 3,4-diaminopyridine in the subject.
• the subject is a human subject.
• the method comprises administering the total daily dose of 3,4- diaminopyridine phosphate salt during each of a plurality of days.
• the botulism is caused by botulinum neurotoxin serotype A.
• the botulism comprises localized botulinum neurotoxin intoxication.
• FIG.1 depicts BoNT/A potency determination and disease progression at 2.5 LD50 of BoNT/A in rats.
• FIG.2 depicts 3,4-DAP pharmacodynamic parameters in na ⁇ ve rats.
• FIG.3A depicts a summary of the experimental strategy of the experiment described in Example 1.
• FIG.3B depicts median ⁇ interquartile ratio (IQR) toxic signs for vehicle and 3,4- DAP-treated rats over time for the experiment described in Example 1.
• FIG.3C depicts survival curves for vehicle and 3,4-DAP-treated rats for the experiment described in Example 1.
• FIG.4 depicts that infusion dose of 3,4-DAP is linearly related to 3,4-DAP steady-state plasma concentrations in rats.
• FIG.5A depicts a summary of the experimental strategy of the experiment described in Example 2.
• FIG.5B depicts median ⁇ IQR toxic signs for at the start of infusion for vehicle and 3,4-DAP-treated rats over time for the experiment described in Example 2.
• FIG.5C depicts survival curves for vehicle and 3,4-DAP-treated rats for the experiment described in Example 2.
• FIG.5D depicts median toxic signs over time for vehicle and 3,4-DAP-treated rats for the experiment described in Example 2.
• FIG.5E depicts normalized weights of surviving rats over time for the experiment described in Example 2.
• FIG.6A–6E depict comparisons of diaphragm endplate success rates, endplate potentials (EPPs), miniature EPPs (mEPPs), and quantal content (QC) among the following groups as described in Example 2: BoNT na ⁇ ve rats; rats intoxicated with 110 U/kg BoNT/A and infused with 3,4-DAP from 1–14 days at 0.98 mg/kg ⁇ h or 1.44 mg/kg ⁇ h and euthanized at 21 days; and rats intoxicated with 110 U/kg BoNT/A and infused with 1.44 mg/kg ⁇ h 3,4-DAP from 1–5 days and euthanized.
• FIG.7A–7B is a table (Table 3) providing details on statistical comparisons.
• 3,4-diaminopyridine also known as amifampridine or 3,4-DAP
• amifampridine is a potential solution to the critical need for a fast-acting, symptomatic treatment for systemic and localized BoNT poisoning that sustains cholinergic neurotransmission until toxicity recedes.
• 3,4-DAP has been used as a drug in the treatment of a number of rare muscle diseases, such as congenital myasthenic syndrome.
• 3,4-DAP is a potassium channel blocker that prolongs action potential duration by reversibly blocking voltage-gated potassium channels, facilitating presynaptic Ca2+ influx and increasing acetylcholine release.3,4-DAP free base form is sold under the trade name Ruzurgi®, which is approved to treat LEMS in pediatric patients.
• 3,4-DAP The phosphate salt of 3,4-DAP is sold under the trade name Firdapse® and is approved to treat LEMS in adults.
• Firdapse® The phosphate salt of 3,4-DAP is sold under the trade name Firdapse® and is approved to treat LEMS in adults.
• 3,4-DAP has been shown to reverse muscle paralysis in isolated mouse diaphragms poisoned by multiple BoNT serotypes, with particularly efficacy in treatment of serotype A. Short-term treatment with 3,4-DAP has been shown to improve respiratory function and prolong survival in mice at terminal stages of botulism, confirming symptomatic efficacy in vivo. However, 3,4-DAP has a short pharmacodynamic half-life.
• the terms “consists essentially of,” “consisting essentially of,” and the like are to be construed as a semi-closed terms, meaning that no other ingredients which materially affect the basic and novel characteristics of an aspect are included.
• the terms “consists of,” “consisting of,” and the like are to be construed as closed terms, such that an aspect "consisting of” a particular set of elements excludes any element, step, or ingredient not specified in the aspect.
• the terms “treat,” “treating,” and “treatment” refer to any indicia of success in the treatment or amelioration of an injury, disease, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, disease, or condition more tolerable to the patient; slowing in the rate of degeneration or decline; or improving a patient’s physical or mental well-being.
• the treatment or amelioration of symptoms can be based on objective or subject parameters, including the results of a physical examination, neuropsychiatric examinations, or psychiatric evaluation.
• the phrase “effective amount” refers to a nontoxic but sufficient amount of the drug or agent to provide the desired effect.
• an amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, the particular active agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case can be determined by one of ordinary skill in the art using routine experimentation. In general, an amount of 3,4-DAP that constitutes an “effective” amount of for treating systemic BoNT intoxication is dependent upon the dose of BoNT that a subject has been exposed to.
• a larger total daily dose of 3,4-diaminopyridine may be needed to achieve efficacy in cases where a subject suffering from systemic BoNT intoxication has been exposed to a larger amount of BoNT, whereas a smaller dose of 3,4-diaminopyridine may be effective in cases where a subject has been exposed to a smaller amount of BoNT. It is within the skill of the ordinarily skilled physician to determine the level of exposure to BoNT and to select, or titrate to, the “effective amount” of 3,4-diaminopyridine needed to treat a subject in need thereof, regardless of whether the subject is suffering from systemic or localized BoNT intoxication.
• the term "pharmaceutically acceptable salt” refers to salts of a basic compound, such as 3,4-DAP, prepared from pharmaceutically acceptable inorganic and organic acids.
• the term “continuous infusion” refers to the administration of a fluid into a subcutaneous space or blood vessel over a prolonged period of time.
• the prolonged period of time can be any suitable duration from about 1 to about 24 hours, such as 1 hour, 2 hours, 3 hours, or 4 hours; or can be any suitable duration such as from about 1 day to about 21 days, or from about 1 week to about 12 weeks.
• BoNT refers to conditions caused by systemic or localized intoxication with BoNTs of any serotype, such as BoNT/A, including the associated muscular and/or respiratory symptoms regardless of the manner in which the condition is acquired.
• toxic sign refers to physiological signs associated with botulism. Toxic signs include respiratory signs, such as abdominal paradox and agonal respiratory pattern; and skeletomuscular signs, such as salivation, lethargy, and total body paralysis.
• BoNT intoxication such as botulism arising from ingesting tainted foods or beverages or from exposure to BoNT, can have serious consequences for afflicted subjects. Without proper treatment, subjects with systemic botulism can suffer from muscle paralysis, respiratory distress, and if left untreated or if treated at too late a stage, death by respiratory collapse.
• BoNT-based pharmaceuticals such as for treating conditions including Miege syndrome, migraines, bruxism, facial wrinkles, limb spasticity, spasmodic dysphonia, and others
• off-target effects resulting from medicinal and/or cosmetic uses of BoNT-based pharmaceuticals are of grave concern, particularly if the BoNT-based pharmaceutical is administered in amount beyond the prescribed or approved amount, if the BoNT-based pharmaceutical is administered in the wrong location, or if the BoNT-based pharmaceutical is properly administered but “leaks” into surrounding tissues.
• Off-target effects of BoNT-based pharmaceuticals include, but are not limited to, unwanted localized muscle weakness or paralysis, ptosis or other muscle drooping, difficulty chewing, and weakness or breathiness of the voice from vocal cord paralysis.
• the present disclosure provides a method of treating botulism in a subject in need thereof, comprising intravenously administering to the subject an effective amount of 3,4-diaminopyridine, or an equivalent amount of a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable vehicle via continuous infusion.
• Infusion of 3,4-DAP can continue for at least one hour, such as 1-24 hours, or for at least one day, such as 1-21 days, or for at least one week, such as 1-12 weeks.
• the effective amount of 3,4-diaminopyridine can be infused at a rate of about 0.1 mg/kg of the subject’s body weight per hour to about 5.0 mg/kg of the subject’s body weight per hour; such as about 0.5 mg/kg per hour to about 4.5 mg/kg per hour, about 1.0 mg/kg per hour to about 4.0 mg/kg per hour, about 1.5 mg/kg per hour to about 3.5 mg/kg per hour, or about 2.0 mg/kg per hour to about 3.0 mg/kg per hour.
• the effective amount of 3,4-diaminopyridine can be infused at a rate of about 0.1 mg/kg of the subject’s body weight per hour, about 0.2 mg/kg of the subject’s body weight per hour, about 0.3 mg/kg of the subject’s body weight per hour, about 0.4 mg/kg of the subject’s body weight per hour, about 0.5 mg/kg of the subject’s body weight per hour, about 0.6 mg/kg of the subject’s body weight per hour, about 0.7 mg/kg of the subject’s body weight per hour, about 0.8 mg/kg of the subject’s body weight per hour, about 0.9 mg/kg of the subject’s body weight per hour, about 1.0 mg/kg of the subject’s body weight per hour, about 1.1 mg/kg of the subject’s body weight per hour, about 1.2 mg/kg of the subject’s body weight per hour, about 1.3 mg/kg of the subject’s body weight per hour, about 1.4 mg/kg of the subject’s body weight per hour,
• the infusion can take place over about 1 to about 24 hours, such as about 2 hours to about 22 hours, about 4 hours to about 20 hours, about 6 hours to about 18 hours, about 8 hours to about 16 hours, or about 10 hours to about 14 hours.
• the infusion can take place over about 1 hour, over about 2 hours, over about 3 hours, over about 4 hours, over about 5 hours, over about 6 hours, over about 7 hours, over about 8 hours, over about 9 hours, over about 10 hours, over about 11 hours, over about 12 hours, over about 13 hours, over about 14 hours, over about 15 hours, over about 16 hours, over about 17 hours, over about 18 hours, over about 19 hours, over about 20 hours, over about 21 hours, over about 22 hours, over about 23 hours, over about 24 hours.
• the infusion of 3,4-DAP can take place at any of the rates described above over more than one day, such as about 3 days to about 21 days, about 5 days to about 19 days, about 7 days to about 17 days, about 9 days to about 15 days, or about 11 days to about 13 days.
• the infusion of 3,4-DAP (or its pharmaceutically acceptable salt) can take place at any of the rates described above over about 1 day, over about 2 days, over about 3 days, over about 4 days, over about 5 days, over about 6 days, over about 7 days, over about 8 days, over about 9 days, over about 10 days, over about 11 days, over about 12 days, over about 13 days, over about 14 days, over about 15 days, over about 16 days, over about 17 days, over about 18 days, over about 19 days, over about 20 days, or over about 21 days.
• the infusion of 3,4-DAP can take place at any of the rates described above over more than one week, such as about 2 weeks to about 12 weeks, about 3 weeks to about 11 weeks, about 4 weeks to about 10 weeks, about 5 weeks to about 9 weeks, or about 6 weeks to about 8 weeks.
• the infusion of 3,4-DAP (or its pharmaceutically acceptable salt) can take place at any of the rates described above over about 1 week, over about 2 weeks, over about 3 weeks, over about 4 weeks, over about 5 weeks, over about 6 weeks, over about 7 weeks, over about 8 weeks, over about 9 weeks, over about 10 weeks, over about 11 weeks, or over about 12 weeks.
• the effective amount of 3,4-diaminopyridine can be provided in a total daily dose ranging from about 1 mg to about 200 mg of 3,4-diaminopyridine, or an equivalent amount of a pharmaceutically acceptable salt thereof, such as about 5 mg to about 195 mg, about 10 mg to about 190 mg, about 15 mg to about 185 mg, about 20 mg to about 180 mg, about 25 mg to about 175 mg, about 30 mg to about 170 mg, about 35 mg to about 165 mg, about 45 mg to about 160 mg, about 50 mg to about 155 mg, about 55 mg to about 145 mg, about 60 mg to about 140 mg, about 65 mg to about 135 mg, about 70 mg to about 130 mg, about 75 mg to about 125 mg, about 80 mg to about 120 mg, about 85 mg to about 115 mg, about 90 mg to about 110 mg, or about 95 mg to about 100 mg.
• a pharmaceutically acceptable salt thereof such as about 5 mg to about 195 mg, about 10 mg to about 190 mg, about 15 mg to about 185 mg,
• the effective amount of 3,4-diaminopyridine can be provided in a total daily dose of about 1 mg, about 5 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, or about 200 mg.
• the subject can be a human subject.
• administering 3,4-diaminopyridine, or the pharmaceutically acceptable salt thereof, as described herein can result in a 3,4-diaminopyridine steady- state blood plasma concentration of about 70 ng/mL to about 200 ng/mL in the subject, such as about 85 ng/mL to about 195 ng/mL, about 90 ng/mL to about 190 ng/mL, about 95 ng/mL to about 185 ng/mL, about 100 ng/mL to about 180 ng/mL, about 105 ng/mL to about 175 ng/mL, about 110 ng/mL to about 165 ng/mL, about 115 ng/mL to about 160 ng/mL, about 120 ng/mL to about 155 ng/mL, about 125 ng/mL to about 150 ng/mL, or about 130 ng/mL to
• administering 3,4-diaminopyridine as described herein can result in a 3,4-diaminopyridine steady-state blood plasma concentration of about 70 ng/mL, about 75 ng/mL, about 80 ng/mL, about 85 ng/mL, about 90 ng/mL, about 95 ng/mL, about 100 ng/mL, about 105 ng/mL, about 110 ng/mL, about 115 ng/mL, about 120 ng/mL, about 125 ng/mL, about 130 ng/mL, about 135 ng/mL, about 140 ng/mL, about 145 ng/mL, about 150 ng/mL, about 155 ng/mL, about 160 ng/mL, about 165 ng/mL, about 170 ng/mL, about 175 ng/mL, about 180 ng/mL, about 185 ng/mL, about 190 ng/m
• the method can comprise administering the total daily dose of 3,4-diaminopyridine or an equivalent amount of a pharmaceutically acceptable salt thereof, via continuous infusion for a plurality of consecutive days at any of the rates described herein.
• the botulism can be caused by botulinum neurotoxin serotype A.
• the present disclosure provides a method of treating botulism in a subject in need thereof, comprising administering to the subject an effective amount of 3,4-diaminopyridine or an equivalent amount of a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable vehicle via a plurality of single bolus injections.
• each of the plurality of single bolus injections comprises about 0.1 mg to about 5.0 mg of 3,4-diaminopyridine, or an equivalent amount of a pharmaceutically acceptable salt thereof, per kg of the subject’s body weight, such as about 0.5 mg/kg to about 4.5 mg/kg, about 1.0 mg/kg to about 4.0 mg/kg, about 1.5 mg/kg to about 3.5 mg/kg, or about 2.0 mg/kg to about 3.0 mg/kg.
• each of the plurality of single bolus injections can comprise about 0.1 mg of 3,4-diaminopyridine, or an equivalent amount of a pharmaceutically acceptable salt thereof, per kg of the subject’s body weight, or about 0.2 mg/kg of the subject’s body weight, about 0.3 mg/kg of the subject’s body weight, about 0.4 mg/kg of the subject’s body weight, about 0.5 mg/kg of the subject’s body weight, about 0.6 mg/kg of the subject’s body weight, about 0.7 mg/kg of the subject’s body weight, about 0.8 mg/kg of the subject’s body weight, about 0.9 mg/kg of the subject’s body weight, about 1.0 mg/kg of the subject’s body weight, about 1.1 mg/kg of the subject’s body weight, about 1.2 mg/kg of the subject’s body weight, about 1.3 mg/kg of the subject’s body weight, about 1.4 mg/kg of the subject’s body weight, about 1.5 mg/kg of the subject’s body
• the present disclosure provides a method of treating botulism in a subject in need thereof, comprising orally administering to the subject an effective amount of 3,4-diaminopyridine phosphate salt.
• the effective amount of 3,4-diaminopyridine phosphate salt can be provided in a total daily dose equivalent to about 1 mg to about 200 mg of 3,4- diaminopyridine freebase, such as a total daily dose equivalent to about 5 mg to about 195 mg, about 10 mg to about 190 mg, about 15 mg to about 185 mg, about 20 mg to about 180 mg, about 25 mg to about 175 mg, about 30 mg to about 170 mg, about 35 mg to about 165 mg, about 45 mg to about 160 mg, about 50 mg to about 155 mg, about 55 mg to about 145 mg, about 60 mg to about 140 mg, about 65 mg to about 135 mg, about 70 mg to about 130 mg, about 75 mg to about 125 mg, about 80 mg to about 120 mg, about 85 mg
• the effective amount of 3,4-diaminopyridine phosphate salt can be provided in a total daily dose equivalent of about 1 mg, about 5 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, or about 200 mg.
• the total daily dose of 3,4-diaminopyridine phosphate salt can be administered in a plurality of single doses per day.
• administering 3,4-diaminopyridine phosphate salt as described herein can result in a steady-state 3,4-diaminopyridine blood plasma concentration of about 70 ng/mL to about 200 ng/mL in the subject, such as about 85 ng/mL to about 195 ng/mL, about 90 ng/mL to about 190 ng/mL, about 95 ng/mL to about 185 ng/mL, about 100 ng/mL to about 180 ng/mL, about 105 ng/mL to about 175 ng/mL, about 110 ng/mL to about 165 ng/mL, about 115 ng/mL to about 160 ng/mL, about 120 ng/mL to about 155 ng/mL, about 125 ng/
• administering 3,4-diaminopyridine phosphate salt as described herein can result in a 3,4-diaminopyridine steady-state blood plasma concentration of about 70 ng/mL, about 75 ng/mL, about 80 ng/mL, about 85 ng/mL, about 90 ng/mL, about 95 ng/mL, about 100 ng/mL, about 105 ng/mL, about 110 ng/mL, about 115 ng/mL, about 120 ng/mL, about 125 ng/mL, about 130 ng/mL, about 135 ng/mL, about 140 ng/mL, about 145 ng/mL, about 150 ng/mL, about 155 ng/mL, about 160 ng/mL, about 165 ng/mL, about 170 ng/mL, about 175 ng/mL, about 180 ng/mL, about 185 ng/mL, about 190
• the method can comprise administering the total daily dose of 3,4-diaminopyridine phosphate salt during each of a plurality of days.
• 3,4-DAP or repeating dosing with 3,4-diaminopyridine could reduce toxic signs and sustain survival in subjects suffering from botulism during the acute stage of the illness, which can persist for up to several weeks, without causing symptoms of neurological toxicity.
• toxic signs in rat subjects lethally challenged with BoNT resolved after a 14 day course of continuous infusion of 3,4-diaminopyridine. Effective daily doses are discussed elsewhere herein.
• compositions suitable for parenteral administration can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
• Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative.
• compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing, and/or dispersing agents.
• formulatory agents such as suspending, stabilizing, and/or dispersing agents.
• the composition can be in the form of a pyrogen- free, parenterally acceptable aqueous solution.
• parenterally acceptable solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
• a composition for intravenous, cutaneous, or subcutaneous injection typically contains an isotonic vehicle.
• compositions for parenteral administration can include aqueous solutions of 3,4-diaminopyridine .
• suspensions 3,4-diaminopyridine can be prepared as appropriate oily injection suspensions.
• Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters.
• Aqueous injection suspensions can contain substances that increase the viscosity of the suspension.
• the suspension also can contain suitable stabilizers or agents that increase the solubility of 3,4-diaminopyridine and allow for the preparation of highly concentrated solutions.
• a composition can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
• 3,4-diaminopyridine also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily.
• 3,4- diaminopyridine compositions can be used in the form of a sterile aqueous solution which can contain other substances, for example, salts or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.
• the present disclosure can include kits comprising one or more compounds or compositions packaged in a manner that facilitates their use to practice methods of treating botulism described herein.
• the kit can include a compound or composition described herein as useful for practice of a method (e.g., a composition comprising 3,4-diaminopyridine ), packaged in a container, such as a sealed bottle or vessel, with a label affixed to the container or included in the kit that describes use of the compound or composition to practice the method of the disclosure.
• the compound or composition can be packaged in a unit dosage form.
• the kit further can further include a device suitable for administering the composition according to the intended route of administration, for example, a syringe or drip bag.
• 3,4-diaminopyridine or its pharmaceutically acceptable salt can be a lyophilate.
• the kit can further comprise an additional container which contains a solution useful for the reconstruction of the lyophilate.
• the effective amount of 3,4-diaminopyridine or pharmaceutically acceptable salt thereof can be provided and/or administered in a pharmaceutical formulation suitable for oral administration, such as a tablet formulation of the phosphate salt sold by Catalyst Pharmaceuticals, Inc. under the trademark Firdapse®.
• the oral formulation can be selected from the group consisting of a solid, a semi-solid, and a liquid oral formulation.
• the solid oral formulation can be a tablet, a pill, a dragee, a powder, a granule, or a capsule.
• Suitable liquid formulations include, for example, aqueous suspensions, solutions, elixirs, and syrups.
• Suitable semi-solid formulations include, for example, oral gels.
• Orally administered pharmaceutical formulations can contain conventional excipients known in the art and can be prepared by conventional methods.
• Orally administered pharmaceutical formulations of the disclosure can contain one or more pharmaceutically acceptable excipients.
• Suitable excipients include fillers such as saccharides, for example lactose or sucrose, mannitol, sodium saccharin or sorbitol, magnesiun carbonate, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
• fillers such as saccharides, for example lactose or sucrose, mannitol, sodium saccharin or sorbitol, magnesiun carbonate, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch
• disintegrating agents can be added such as the above-mentioned starches and also carboxymethyl-starch, cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate and sodium starch glycolate.
• Suitable excipients also include flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol; sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation.
• dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
• suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences pp.1447-1676 (Alfonso R. Gennaro ed., 19th ed.1995), incorporated herein by reference.
• the excipients are of pharmaceutical grade.
• 3,4-diaminopyridine or a salt thereof can be micronized before preparing the oral formulations. Methods known in the art can be used for micronization of 3,4-diaminopyridine or its salts.
• a typical industrial mill is composed of a cylindrical metallic drum that usually contains steel spheres. As the drum rotates the spheres inside collide with the particles of the solid, thus crushing them towards smaller diameters. In the case of grinding, the solid particles are formed when the grinding units of the device rub against each other while particles of the solid are trapped in between. Methods like crushing and cutting can also be used for reducing particle diameter. Crushing employs hammer-like tools to break the solid into smaller particles by means of impact. Cutting uses sharp blades to cut the rough solid pieces into smaller ones. In addition, modern micronization methods that use supercritical fluids in the micronization process can be used.
• Suitable techniques include the RESS process (Rapid Expansion of Supercritical Solutions), the SAS method (Supercritical Anti-Solvent) and the PGSS method (Particles from Gas Saturated Solutions). These modern techniques allow for greater tuneability of the process. Parameters like relative pressure and temperature, solute concentration, and antisolvent to solvent ratio can be varied to adjust to obtain the desired particle size.
• the supercritical fluid methods result in finer control over particle diameters, distribution of particle size and consistency of morphology.
• micronized 3,4-diaminopyridine or its salt suitable for use in the oral formulations of the present disclosure can be a composition where 90% or more of the particles have a particle size of 20 microns or less (i.e., ⁇ 20 ⁇ m).
• the oral pharmaceutical formulations of the present disclosure comprise micronized 3,4- diaminopyridine phosphate salt.
• 90% or more of the particles in the micronized 3,4-diaminopyridine phosphate salt have a particle size of 20 microns or less.
• Example 1 Serial administration of 3,4-DAP prolongs survival following lethal challenge with BoNT/A.
• 3,4-DAP would reverse botulism toxicity in rats, the effects of repeated 3,4-DAP administration were first evaluated in rats lethally challenged by intravenous administration of 110 U/kg BoNT/A (2.5 LD50; see Figure 1A).
• Figure 1 generally depicts BoNT/A potency determination and disease progression at 2.5 LD50 in rats.
• Figure 1A depicts determination of rat intravenous LD50. Rats were administered 22–69 U/kg BoNT/A by tail vein injection and monitored for survival at 24 h intervals through 7 d. Surviving rats were bright, alert and responsive at 7 d with receding toxic signs of botulism. The LD50 was calculated from survival outcomes using simple linear regression.
• Figure 1C depicts the survival curve for rats from Figure 1B. Details on statistical comparisons are presented in Figure 7A-7B (Table 3).
• Figure 2A depicts a summary of this experimental strategy.
• Figures 2B-2D depict that 3,4-DAP treatment (trend lines “a”) elicits transient increases in VO2 ( Figure 2B), respiratory rate (Figure 2C) and tidal volume ( Figure 2D).
• Mean values were compared to vehicle (trend lines “b”) at each time point using two-way repeated measures ANOVA followed by Sidak’s multiple comparisons test.
• samples were collected in 5 min bins
• Figure 2C and Figure 2D values were collected at 30 min intervals.
• FIG. 3B depicts median ⁇ interquartile ratio (IQR) toxic signs for vehicle (trend line “a”) and 3,4-DAP-treated (trend line “b”) rats over time (repeated measures two-way ANOVA with Sidak’s multiple comparisons test at each time point).
• IQR median ⁇ interquartile ratio
• Figure 4 generally depicts that infusion dose is linearly related to 3,4-DAP steady- state concentrations.
• 3,4-DAP was continuously infused to lethally intoxicated rats through subcutaneous catheters.
• IDR infusion dose rate
• CSS was determined by linear regression.
• FIG. 4B the best-fit equation is presented above the graph.
• Behavioral signs of neurological toxicity were not observed during infusion at any dose (see “infusion” section of Table 1 above). Details on statistical comparisons are presented in Figure 7A-7B (Table 3).
• Figure 5 generally depicts that continuous infusion of 3,4-DAP has both symptomatic and antidotal effects in lethally intoxicated rats.
• rats were lethally intoxicated with 2.5 LD50 BoNT/A and randomized into treatment or vehicle groups Toxic signs, weight, and survival were monitored at 24 h intervals. Gray boxes represent infusion period.
• FIG. 5A depicts a summary of the experimental strategy.
• These infusion doses were intended to generate 3,4-DAP blood levels within the clinical range produced by oral dosing.
• Figure 5C depicts survival curves for each treatment group (Mantel-Cox log-rank test; overall p ⁇ 0.0001). Trend line “a” corresponds to the saline-vehicle group. Trend line “b” corresponds to the group administered 3,4-DAP at 0.54 mg/ kg ⁇ h.
• Trend line “c” corresponds to the group administered 3,4-DAP at 0.98 mg/ kg ⁇ h
• Trend line “d” corresponds to the group administered 3,4-DAP at 1.44 mg/ kg ⁇ h. These designations are consistent through panels C-E. Significance indicators indicate pairwise comparisons made to the saline-vehicle vehicle group. The median survival time of vehicle-infused rats was 2.5 d (range: 2.0–4.5 d). Among all treatment conditions, infusion with 3,4-DAP improved survival proportions (p ⁇ 0.0001) and median survival time (p ⁇ 0.0001) compared to vehicle. Pairwise analyses revealed a clear dose-dependent effect of 3,4- DAP infusion rate on survival.
• Figure 5D depicts median toxic signs for each group over time (two-way ANOVA with Tukey’s; overall p ⁇ 0.0001). Significance indicators indicate pairwise comparisons made to vehicle. Toxic signs stabilized by 2 d in surviving rats as moderate abdominal paradox, limb weakness and salivation, and resolved by 14 d, at which time infusion was stopped. Toxic signs were improved by infusion with 0.98 mg/kg ⁇ h or 1.44 mg/kg ⁇ h 3,4- DAP compared to vehicle (p ⁇ 0.0001), indicating continuous infusion had sustained symptomatic benefit.
• the 5 d time point was chosen because (1) 100% of vehicle-infused rats were deceased by 5 d, indicating the decline in respiratory function below the level sufficient for survival, and (2) toxic signs reached a maximum between 3-5 d in 3,4-DAP-infused survivors, suggesting that paralysis reached peak severity. Following cessation of 3,4-DAP infusion, toxic signs worsened within 3-6 h and all rats were deceased within 12 h. The need for continuous treatment with 3,4- DAP beyond 5 d suggested that antidotal efficacy resulted from sustained symptomatic benefits. Survivors of lethal BoNT/A challenge exhibited significant recovery of neurophysiological function from 5 to 21 d.
• FIG. 6 generally depicts the time-dependent recovery of diaphragm endplate potentials in 3,4-DAP infused intoxicated rats.
• EPPs evoked endplate potentials
• mEPPs spontaneous miniature endplate potentials
• FIGS. 6B-6E depict mean ⁇ SEM scatter dot plots for (B) EPP amplitudes, (C) mEPP frequencies, (D) QC and (E) mEPP amplitudes.
• this multimodal therapy can be a comprehensive treatment strategy for botulism. Moreover, the majority of botulism patients continue to exhibit neurological deficits and muscle weakness after discharge. Although the pathophysiologies responsible for persistent symptoms remain unknown, they can be related to depressed neurotransmission (as suggested by Figure 3), and likewise susceptible to 3,4-DAP treatment. [0127] Previous efforts to understand the toxic mechanisms of BoNT on neurotransmission have relied on either supraphysiological intoxication of isolated diaphragm muscle preparations or local administration of paralytic doses to skeletal muscles, neither of which recapitulate the toxicokinetics of a systemic lethal challenge.
• botulism cases usually involve less than 5 LD50, in rare cases exposures can exceed 100 LD50.
• 3,4- DAP can be less effective in more severely paralyzed muscles, suggesting 3,4- DAP can have reduced efficacy in cases involving higher BoNT doses.
• such reduced efficacy can be at least partially ameliorated as neuromuscular junction repair progresses, thereby reducing total recovery time.

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Toxicology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85239795

Family Applications (1)

Country Status (4)

Citations (3)

Family Cites Families (1)

• 2022
  • 2022-08-11 WO PCT/US2022/074849 patent/WO2023023463A1/en not_active Ceased
  • 2022-08-11 EP EP22859290.3A patent/EP4387620A4/en active Pending
  • 2022-08-11 US US17/819,111 patent/US20230074200A1/en active Pending
  • 2022-08-11 JP JP2024508945A patent/JP2024534032A/ja active Pending

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events